ZLAB
What one share of Zai Lab Limited holds
Pharmaceutical Preparations
We are a patient-focused, innovative, commercial-stage, global biopharmaceutical company with a substantial presence in both Greater China and the United States. We are focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease.
Zai Lab Limited’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.41 |
|---|---|
| Profit | −$0.17 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.13 |
| Cash and investments | $0.54 |
| Book value | $0.54 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$0.40 | $0.02 | −$0.36 | — | −$0.53 |
| 2017 | — | −$0.23 | $0.04 | −$0.19 | — | — |
| 2018 | — | −$0.26 | $0.02 | −$0.20 | — | $0.43 |
| 2019 | $0.02 | −$0.30 | $0.01 | −$0.31 | — | $0.43 |
| 2020 | $0.06 | −$0.35 | $0.01 | −$0.29 | — | $1.33 |
| 2021 | $0.16 | −$0.76 | $0.02 | −$0.61 | — | $1.45 |
| 2022 | $0.22 | −$0.46 | $0.03 | −$0.41 | — | $1.09 |
| 2023 | $0.28 | −$0.35 | $0.01 | −$0.21 | — | $0.82 |
| 2024 | $0.40 | −$0.26 | $0.01 | −$0.22 | — | $0.78 |
| 2025 | $0.42 | −$0.16 | $0.01 | −$0.15 | — | $0.65 |